Kolexia
Hrab Ioana Oncologie médicale
Hrab Ioana
Oncologie médicale
Centre François-Baclesse
Caen, France
94 Activités
315 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Tumeurs du cerveau Nausée Hémorragie Hémorragie cérébrale Vomissement Tumeurs du sein triple-négatives Lymphopénie

Collaborateurs

Voir plus
Levy Christelle
Levy Christelle
Centre François-Baclesse, Caen, France
Allouache Djalila
Allouache Djalila
Centre François-Baclesse, Caen, France
Segura-Djezzar Carine
Segura-Djezzar Carine
Centre François-Baclesse, Caen, France
Morel Adeline
Morel Adeline
Centre François-Baclesse, Caen, France

Industries

Voir plus
A+A
18 collaboration(s)
Dernière en 2023
Novartis
6 collaboration(s)
Dernière en 2023
MSD
4 collaboration(s)
Dernière en 2023
Lilly
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
STEREO-HBM: Stereotactic Radiotherapy for Cerebral Metastases With Recent Hemorrhagic Signal: Phase 2 Study in 2 Steps
Essai Clinique (Centre François-Baclesse)   22 décembre 2023
255P Prognostic stratification capacity of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
InTTercePT: Treatment With Tucatinib in Addition to Pertuzumab and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer After Local Therapy of Isolated Brain Progression
Essai Clinique (Seagen)   21 septembre 2023
TRIPLEX: Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment
Essai Clinique (Centre François-Baclesse)   31 juillet 2023
WEBAPPAC: Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer
Essai Clinique (Centre François-Baclesse)   31 juillet 2023
112P Correlation between HER2-negative status and risk of recurrence according to PAM50 score
Abstract Book of ESMO Breast Cancer 2023, Berlin, Germany, 11-13 May 2023   01 mai 2023
Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors.
Frontiers in oncology   19 janvier 2023
HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
BMC cancer   20 octobre 2022
465P Larotracking: Real-life study of locally advanced/metastatic solid tumor treated with larotrectinib in French expanded access program
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
104P HELENA: Study of HER2-low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
Abstract Book of ESMO Breast Cancer 2022, Berlin, Germany, 03-05 May 2022   01 mai 2022